Citigroup Inc. reaffirmed their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report issued on Thursday. Citigroup Inc. currently has a $575.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies increased their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an overweight rating in a report on Tuesday, June 20th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a hold rating in a report on Monday, May 15th. Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Jefferies Group LLC reissued a hold rating and issued a $471.00 price objective (up from $418.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Leerink Swann reissued an outperform rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $496.35.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at 471.49 on Thursday. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The stock has a market capitalization of $49.99 billion, a price-to-earnings ratio of 47.30 and a beta of 1.65. The firm’s 50-day moving average is $483.45 and its 200-day moving average is $442.76.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Citigroup Inc. Reiterates Buy Rating for Regeneron Pharmaceuticals, Inc. (REGN)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/11/citigroup-inc-reiterates-buy-rating-for-regeneron-pharmaceuticals-inc-regn.html.

In related news, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi acquired 166,415 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 129,257 shares of company stock worth $61,745,394. Corporate insiders own 10.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Alpha Windward LLC boosted its stake in shares of Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 1 shares during the last quarter. Concert Wealth Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% during the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 3 shares during the last quarter. Cleararc Capital Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.3% during the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 5 shares during the last quarter. Regentatlantic Capital LLC boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 5 shares during the last quarter. Finally, Capital Planning Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 12 shares during the last quarter. 67.96% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.